ArticleCureus2026
Ionized Plasma Jet Therapy for the Treatment of Striae Distensae.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStriae distensae are common linear atrophic skin lesions caused by alterations in collagen, elastin, and other components of the extracellular matrix. Available treatments often provide inconsistent improvement, particularly in mature striae albae.
objectiveThis study aimed to evaluate the safety and efficacy of ionized plasma jet therapy (IPJT) in the treatment of striae distensae. METHODOLOGY: This open-label experimental study included 30 patients aged 15-49 years who met the predefined eligibility criteria. Participants underwent four sessions of IPJT using the Jett Plasma Lift Medical device (JETT; COMPEX, spol. s r.o., Brno, Czech Republic). Ablative and non-ablative treatments were administered alternately at 15-day intervals, with two sessions of each modality. Clinical improvement was evaluated through blinded photographic assessment using a five-point scale ranging from no improvement to excellent improvement. Procedural pain and adverse effects, including edema, itching, erythema, hypopigmentation, and hyperpigmentation, were assessed during follow-up visits for up to 90 days.
resultsThe mean age of the participants was 28 ± 5.4 years; 18 (60.0%) were female and 12 (40.0%) were male. Striae albae were present in 28 (93.3%) patients, whereas 2 (6.7%) had striae rubrae. Excellent improvement was observed in 5 (16.7%) patients, good improvement in 19 (63.3%), and moderate improvement in 6 (20.0%). Post-inflammatory hyperpigmentation occurred in three (10.0%) patients and resolved following treatment with a topical depigmenting agent. The mean procedural pain score was 2.2 ± 0.6 on the visual analogue scale. No persistent edema, erythema, itching, scarring, hypopigmentation, or serious treatment-related adverse events were observed.
conclusionIPJT demonstrated promising clinical improvement, with mild procedural discomfort and a low frequency of temporary adverse effects in patients with striae distensae. However, larger randomized controlled trials using validated assessment tools and balanced representation of different striae subtypes are required to further establish its safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.